Financial Performance - For the six months ended June 30, 2022, the company reported a revenue of RMB 377,295,000, representing a 25.2% increase from RMB 301,326,000 in the same period of 2021[4] - Gross profit for the same period was RMB 297,844,000, up 24.5% from RMB 239,108,000 year-on-year[4] - Operating profit increased to RMB 92,043,000, a 46.8% rise compared to RMB 62,694,000 in the previous year[4] - The net profit attributable to shareholders was RMB 77,255,000, reflecting a 57.7% increase from RMB 48,977,000 in the prior year[4] - Basic earnings per share rose to 13.79 cents, compared to 8.74 cents in the same period last year, marking a 57.5% increase[4] - The company's revenue for the six months ended June 30, 2022, was RMB 389,825,000, representing a 25.9% increase from RMB 309,297,000 in the same period of 2021[15] - The operating profit for the six months ended June 30, 2022, was RMB 77,255,000, compared to RMB 48,977,000 for the same period in 2021, marking a 57.8% increase[19] - The basic earnings per share for the six months ended June 30, 2022, was RMB 0.138, up from RMB 0.087 in the same period of 2021[19] - The company's net profit for the six months ended June 30, 2022, was RMB 77,255,000, compared to RMB 48,977,000 for the same period in 2021, indicating a 57.8% growth[19] - The gross margin for the six months ended June 30, 2022, was approximately 78.9%, a decrease of 0.5% from 79.4% for the same period in 2021[45] Assets and Liabilities - Total assets as of June 30, 2022, amounted to RMB 2,595,530,000, compared to RMB 2,072,313,000 at the end of 2021[5] - Current assets increased to RMB 1,017,610,000 from RMB 889,873,000, indicating a growth of 14.4%[5] - The company's cash and cash equivalents rose to RMB 84,671,000, up from RMB 55,294,000, representing a 53.2% increase[5] - Total liabilities increased to RMB 585,917,000 from RMB 571,794,000, showing a slight rise of 2.5%[7] - The company maintained a stable equity position with total equity reaching RMB 1,531,004,000, up from RMB 1,453,749,000, reflecting a growth of 5.3%[7] - The total assets of the company as of June 30, 2022, were RMB 1,531,004,000, an increase from RMB 1,394,459,000 as of December 31, 2021[19] - Inventory as of June 30, 2022, totaled RMB 104,541,000, up from RMB 86,313,000 as of December 31, 2021[37] - Trade receivables as of June 30, 2022, amounted to RMB 272,296,000, compared to RMB 230,252,000 as of December 31, 2021[39] Operational Developments - The company has established a new R&D inspection center equipped with advanced facilities for new product development and quality control, officially in use since September 2021[46] - The company plans to officially launch the renovated biochemical extraction workshop in 2022 to meet market demand[46] - The company aims to continue developing potential business opportunities to drive future growth[54] Shareholder Information - As of June 30, 2022, Mr. Zhang Hong holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[56] - Mr. Zhang Xiaoguang owns 42,315,000 shares, accounting for 10.91% of domestic shares and 7.55% of total registered capital[56] - Huinan County Caiyuan Investment Co., Ltd. holds 81,975,000 shares, which is 21.14% of domestic shares and 14.63% of total registered capital[60] Corporate Governance - The audit committee consists of three independent non-executive directors, ensuring oversight of the company's financial processes and internal controls[66] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM Listing Rules[63] - No arrangements were made for directors or senior management to acquire rights to benefit from purchasing the company's shares or bonds during the reporting period[57] - The company did not identify any other individuals holding interests or short positions in the company's shares outside of the disclosed parties as of June 30, 2022[61] - The chairman and CEO roles are held by the same individual, Mr. Zhang Hong, which the board believes does not affect accountability or independent decision-making[64] Employment and Share Transactions - The company employed 956 staff members as of June 30, 2022, an increase from 951 staff members a year earlier[67] - The company did not repurchase, sell, or redeem any of its listed shares during the six-month period ending June 30, 2022[68]
吉林长龙药业(08049) - 2022 - 中期财报